Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Clinical trial NCT06895733 · RECRUITING

Trial details

NCT number: NCT06895733
Sponsor: Tianjin Medical University Second Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor, Adult Next-generation Sequencing Precision Medicine

Start date: 2024-11-27
Primary completion: 2025-12-01
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.